T. Rowe Price Investment Management
NRIX icon

T. Rowe Price Investment Management’s Nurix Therapeutics NRIX Stock Holding History

T. Rowe Price Investment Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-172,838
Closed -$3.28M – 842
2025
Q4 		$3.28M Sell
172,838
-1,024,577
-86% -$14.7M ﹤0.01% 597
2025
Q3 		$11.1M Sell
1,197,415
-1,276,541
-52% -$13.3M 0.01% 552
2025
Q2 		$28.2M Buy
2,473,956
+45,673
+2% +$494K 0.02% 457
2025
Q1 		$28.8M Buy
2,428,283
+47,855
+2% +$800K 0.02% 475
2024
Q4 		$44.8M Sell
2,380,428
-167,663
-7% -$3.84M 0.03% 424
2024
Q3 		$57.3M Buy
2,548,091
+358,899
+16% +$8.13M 0.03% 383
2024
Q2 		$45.7M Buy
+2,189,192
New +$34.1M 0.03% 398
2023
Q1 		– Sell
-432,161
Closed -$4.75M – 560
2022
Q4 		$4.75M Sell
432,161
-560,267
-56% -$6.76M ﹤0.01% 524
2022
Q3 		$12.9M Buy
+992,428
New +$15.7M 0.01% 485

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

T. Rowe Price Investment Management's NRIX Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 172,838 shares — an estimated $3.28M sold.

T. Rowe Price Investment Management first reported a position in NRIX in Q3 2022 and held it in 9 quarters. The position peaked at $57.3M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 172,838 Nurix Therapeutics shares in Q1 2026, an estimated $3.28M.
  • T. Rowe Price Investment Management first reported a position in Nurix Therapeutics in Q3 2022 and held it in 9 quarters.
  • T. Rowe Price Investment Management's Nurix Therapeutics position peaked at $57.3M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.